BLA Submission (Ph2 data)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Balstilimab (AGEN2034) in Recurrent/Metastatic Cervical Cancer
ClinicalTrial.gov (NCT03104699): Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer
ClinicalTrial.gov (NCT03894215): Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
ClinicalTrial.gov (NCT03495882): Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
WHAT IS THE NEXT CATALYST EVENT?
Completion of BLA Submission (initiation of rolling submission 9/18/20)
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
TBD (rolling submission started (see 9/18/20 PR)
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials . O'Malley, et al.
MECHANISM OF ACTION
Balstilimab is a novel anti-PD-1 human monoclonal antibody that has demonstrated promising clinical benefit in second line treatment of cervical cancer.
Updated by MV
#AGEN, #Balstilimab, #AGEN2034, #anti-PD1, #PD-1, #antiPD1, #PD1, #antibody, #cervical cancer, #cancer, #recurrent cervical cancer, #metastatic cervical cancer, #metastatic cancer
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post